Loss of lactate dehydrogenase B subunit expression is correlated with tumour progression and independently predicts inferior disease-specific survival in urinary bladder urothelial carcinoma

Pathology

Volumn 43, Issue 7, 2011, Pages 707-712

  Liao, Alex C ^a,b   Li, Chien Feng ^a,b,c   Shen, Kun Hung ^a,d,e   Chien, Lan Hsiang ^f   Huang, Hsuan Ying ^g   Wu, Ting Feng ^f  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^f SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^g CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

LDH B; Prognosis; Proteomics; Urinary bladder urothelial carcinoma

Indexed keywords

EID: 84863238632     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32834bf67a     Document Type: Article

References (33)

1. Bane BL, Rao JY, Hemstreet GP. Pathology and staging of bladder cancer. Semin Oncol 1996; 23: 546-70. (Pubitemid 26362216)
2. Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998; 160: 645-59. (Pubitemid 29479481)
3. Zieger K, Wolf H, Olsen PR, Hojgaard K. Long-term follow-up of non-invasive bladder tumours (stage Ta): recurrence and progression. BJU Int 2000; 85: 824-8. (Pubitemid 30242785)
4. Dey P. Urinary markers of bladder carcinoma. Clin Chim Acta 2004; 340: 57-65. (Pubitemid 38167508)
5. Bassi P, De Marco V, De Lisa A, et al. Non-invasive diagnostic tests for bladder cancer: a review of the literature. Urol Int 2005; 75: 193-200. (Pubitemid 41433864)
6. Nelson DL, Cox MM. Lehninger Principles of Biochemistry. 3rd ed. New York: Worth Publisher; 2000; Chapter 15, Glycolysis and the catabolism of hexoses.
7. Nelson DL, Cox MM. Lehninger Principles of Biochemistry. 3rd ed. New York: Worth Publisher; 2000; Chapter 19, Oxidative phosphorylation and photophosphorylation.
8. Holbrook JJ, Liljas A, Steindel SJ, Rossman MG. Lactate dehydrogenase. In: Boyer PD, editor. The Enzymes. 3rd ed. New York: Academic Press, 1975; 191-292.
9. Koukourakis MI, Giatromanolaki A, Sivridis E. Tumour and Angiogenesis Research Group. Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumour Biol 2003; 24: 199-202. (Pubitemid 37500569)
10. Sheng KH, Yao YC, Chuang SS, Wu H, Wu TF. Search for the tumor-related proteins of transition cell carcinoma in Taiwan by proteomic analysis. Proteomics 2006; 6: 1058-65. (Pubitemid 43260230)
11. Giatromanolaki A, Harris AL. Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer. Anticancer Res 2001; 21: 4317-24. (Pubitemid 34245369)
12. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001; 18: 243-59. (Pubitemid 34044509)
13. Markert CL, Shaklee JB, Whitt GS. Evolution of a gene. Multiple genes for LDH isozymes provide a model of the evolution of gene structure, function and regulation. Science 1975; 189: 102-14.
14. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49: 6449-65. (Pubitemid 20008770)
15. Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 2000; 6: 15-9. (Pubitemid 30010232)
16. Martínez-Zaguilán R, Seftor EA, Seftor RE, et al. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1996; 14: 176-86. (Pubitemid 26074280)
17. Rozhin J, Sameni M, Ziegler G, Sloane BF. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 1994; 54: 6517-25.
18. Murray B, Wilson DJ. A study of metabolites as intermediate effectors in angiogenesis. Angiogenesis 2001; 4: 71-7. (Pubitemid 34032039)
19. Tas F, Aykan F, Alici S, Kaytan E, Aydiner A, Topuz E. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 2001; 24: 547-50. (Pubitemid 33131412)
20. Ferrari S, Bertoni F, Mercuri M, et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol 2001; 12: 1145-50. (Pubitemid 32834497)
21. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-40. (Pubitemid 29368255)
22. Hauschild A, Michaelsen J, Brenner W, et al. Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 1999; 9: 155-61. (Pubitemid 29331524)
23. Kondo E, Ogura M, Kagami Y, et al. Assessment of prognostic factors in follicular lymphoma patients. Int J Hematol 2001; 73: 363-8. (Pubitemid 33758995)
24. Yuce K, BaykalC, Genc C, Al A, Ayhan A.Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer. Eur J Gynaecol Oncol 2001; 22: 228-32. (Pubitemid 32757877)
25. Argiris A, Murren JR. Staging and clinical prognostic factors for small-cell lung cancer. Cancer J 2001; 7: 437-47.
26. Tas F, Aydiner A, Demir C, Topuz E. Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol 2001; 24: 376-8. (Pubitemid 32730733)
27. Ryberg M, Nielsen D, Osterlind K, Skovsgaard T, Dombernowsk P. Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol 2001; 12: 81-7. (Pubitemid 32162451)
28. Wilder RB, Rodriguez MA, Ha CS, et al. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer 2001; 91: 2440-6. (Pubitemid 32552833)
29. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Tumour and Angio-genesis Research Group. Lactate dehydrogenase-5 (LDH-5) overexpres-sion in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 2003; 89: 877-85. (Pubitemid 37175811)
30. Ebert BL, Bunn HF. Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and p300/CREB binding protein. Mol Cell Biol 1998; 18: 4089-96. (Pubitemid 28287932)
31. Grayhack JT, Lee C, Oliver L, Schaeffer AJ, Wendel EF. Biochemical profiles of prostatic fluid from normal and diseased prostate glands. Prostate 1980; 1: 227-37.
32. Leiblich A, Cross SS, Catto JW, et al. Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer. Oncogene 2006; 25: 2953-60. (Pubitemid 43739247)
33. Ding SJ, Li Y, Shao XX, et al. Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics 2004; 4: 982-94. (Pubitemid 38445958)